NRX Pharmaceuticals: enters DARPA contract for $11,200,000

What happened The filing reports that NRx Defense, a subsidiary of NRX Pharmaceuticals, entered into a prime contract with the Defense Advanced Research Projects Agency (DARPA) on Sep 29, 2026 to conduct the Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) clinical trial. The contract has an aggregate value of approximately $11,200,000, of which $6,700,000 has been initially obligated by DARPA. The company issued a press release announcing the award on Sep 30, 2026.

Key details

• Contract value approximately $11,200,000, with $6,700,000 initially obligated and additional funding subject to appropriations and DARPA funding options.
• 18-month performance period; payments are made upon achievement and acceptance of specified program milestones.
• Subject to certain government rights, NRx Defense retains ownership of inventions conceived or first actually reduced to practice under the contract; DARPA receives a nonexclusive, nontransferable, irrevocable, paid-up license for governmental purposes.
• The SPARC-TMS trial is designed to evaluate a single-day treatment protocol using robotic neuro-navigated transcranial magnetic stimulation in combination with NRX-101 for treatment-resistant depression; the trial has been approved by the U.S. Food and Drug Administration and is expected to begin enrolling patients.

Why it may matter This report was filed under Item 1.01 (entry into a material definitive agreement), which covers the prime contract between NRx Defense and DARPA described above. The filing does not show why the insider traded or why the company acted.